Comparing cytotoxicity of parthenolide, melphalan, and procarbazine in colon adenocarcinoma and hepatocellular carcinoma cells

Author
Fatemeh B. Rassouli
Abstract
Introduction: Colon adenocarcinoma and hepatocellular carcinoma are among the most prevalent cancers in Iran. Since chemotherapy resistance is a major obstacle in the treatment of these malignancies, it is necessary to introduce novel and more effective anticancer regimens. The purpose of this study was to compare cytotoxicity of parthenolide, a sesquiterpene lactone, with alkylating agents melphalan and procarbazine.

Materials and Methods: To compare toxic effects of parthenolide, melphalan and procarbazine, human colon adenocarcinoma and hepatocellular carcinoma cell lines were used. The viability of HT29 and HepG2 cells was evaluated by MTT assay 24, 48 and 72 h after treatment, and cells were checked for morphological alterations by the end of each time point.

Results: The IC50 values of parthenolide and melphalan in HT29 cells were determined as 8.5 and 160 mg/mL, respectively, while the highest concentration of procarbazine reduced cell viability by only 5%. In addition, the IC50 values of parthenolide and melphalan in HepG2 cells calculated as 15 and 80 mg/mL, respectively, while 160 mg/mL procarbazine reduced cell viability by 11%. To note, morphological changes confirmed MTT results in both cell lines.

Conclusion: Findings of the current study indicated that parthenolide induced more cytotoxic effects in comparison with alkylating drugs. Since this terpenoid derivative effectively reduced the viability of HT29 and HepG2 cells, it could be considered as a potent agent to design new chemotherapy regimens against colon and liver cancers.
Keywords
Colon adenocarcinoma
Hepatocellular carcinoma
Parthenolide
Melphalan
Procarbazine
Cytotoxicity
Ganji A, Malekzadeh F, Safavi M, Nasseri Moghaddam S, M Nourie, Shahin Merat, et al. Digestive and liver disease statistics in Iran. Middle East Journal of Digestive Diseases 2009;1(2):56-62.
Dolatkhah R, Somi MH, Bonyadi MJ, AsvadiKermani I, Farassati F, Dastgiri S. Colorectal cancer in Iran: molecular epidemiology and screening strategies. J Cancer Epidemiol 2015;2015:643020.
Mirzaei M, Ghoncheh M, Pournamdar Z, Soheilipour F, Salehiniya H. Incidence and trend of liver cancer in Iran. J Coll Physicians Surg Pak 2016;26(4):306-9.
Watson AJ, Collins PD. Colon cancer: a civilization disorder. Dig Dis 2011;29(2):222-8.
Haddock MG. Intraoperative radiation therapy for colon and rectal cancers: a clinical review. Radiation Oncology 2017;12:11.
Kong FC, Zhang JQ, Zeng C, Chen WL, Ren WX, Yan GX, et al. Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6. J Huazhong Univ Sci Technolog Med Sci 2015;35(3):343-9.
Mathema VB, Koh YS, Thakuri BC, Sillanpää M. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation 2012;35(2):560-5.
Li Y, Zhang Y, Fu M, Yao Q, Zhuo H, Lu Q, et al. Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma. Mol Med Rep 2012;6(3):477-82.
Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007;13(1):59-67.
Zhao X, Liu X, Su L. Parthenolide induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung cancer cells. J Exp Clin Cancer Res 2014;33(1):3.
Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett 2007;254(1):119-27.
Carlisi D, Lauricella M, D'Anneo A, Buttitta G, Emanuele S, di Fiore R, et al. The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells. J Cell Physiol 2015;230(6):1276-89.
Kim SL, Kim SH, Trang KT, Kim IH, Lee SO, Lee ST, et al. Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett 2013;335(2):479-86.
Wesierska-Gadek J, Skladanowski A. Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes. Future Medical Chemistry 2012;4(1):51-72.
Kuczma M, Ding ZC, Zhou G. Immunostimulatory effects of melphalan and usefulness in adoptive cell therapy with antitumor CD4+ T cells. Critical Reviews in Immunology 2016;36(2):179-91.
Armand JP, Ribrag V, Harrousseau JL, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag 2007;3(2):213-24.
Kraft SL, Baker NM, Carpenter J, Bostwick JR. Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity. Psychooncology 2014;23(1):108-13.
Parada-Turska J, Paduch R, Majdan M, Kandefer-Szerszeń M, Rzeski W. Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol Rep 2007;59(2):233-7.
Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, Schmidt CM. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg 2012;16(7):1333-40.
Nakabayashi H, Shimizu K. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer 2012;12(1):453.
Pinguet F, Bressolle F, Culine S, Fabbro M, Astre C, Chevillard C. Influence of the schedule of exposure on the cytotoxic effect of melphalan on human 8226 and A2780 cells. Eur J Cancer. 1999;35(9):1402-6.
Mougenot P, Bressolle F, Culine S, Solassol I, Poujol S, Pinguet F. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer. Anticancer Res 2006;26(3B):2197-203.
Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood 2015;125(20):3100-4.
Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, et al. A phase I new approaches to neuroblastoma therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent/refractory high-risk neuroblastoma. Pediatr Blood Cancer 2016;63(8):1349-56.
Esma F, Salvini M, Troia R, Boccadoro M, Larocca A, Pautasso C. Melphalan hydrochloride for the treatment of multiple myeloma. Expert Opin Pharmacother 2017;18(11):1127-36.
Park GB, Kim YS, Kim D, Kim S, Lee HK, Cho DH, et al. Melphalan-induced apoptosis of EBV-transformed B cells through upregulation of TAp73 and XAF1 and nuclear import of XPA. J Immunol 2013;191(12):6281-91.
Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, et al. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res 2014;2:12.
Tagami K, Tanda S, Kato H, Tashiro A, Saji K, Komaru T, et al. Detection of asymptomatic cardiac metastasis and successful salvage chemotherapy comprising a prednisone, etoposide, procarbazine, and cyclophosphamide regimen in an elderly Japanese patient suffering from a delayed recurrence of diffuse large B-cell lymphoma. Case Rep Oncol 2012;5(1):62-8.
Taal W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, Wertenbroek AA, Bromberg JE, et al. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetic. Journal of Neurooncology 2015;121(2):365-72.